Metropolitan Life Insurance Company (MetLife)’s Corbus Pharmaceuticals CRBP Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-718	Closed	-$181K	–	2568
2020 Q2	$181K	Hold	718	–	–	﹤0.01%	1868
2020 Q1	$113K	Buy	718 +4	+0.6%	+$676	﹤0.01%	1957
2019 Q4	$117K	Buy	714 +174	+32%	+$25.7K	﹤0.01%	2242
2019 Q3	$78.8K	Sell	540 -59	-10%	-$10.3K	﹤0.01%	2431
2019 Q2	$124K	Buy	599 +108	+22%	+$23.1K	﹤0.01%	2198
2019 Q1	$102K	Sell	491 -75	-13%	-$16.5K	﹤0.01%	2313
2018 Q4	$99.1K	Hold	566	–	–	﹤0.01%	2275
2018 Q3	$128K	Hold	566	–	–	﹤0.01%	2302
2018 Q2	$85.7K	Hold	566	–	–	﹤0.01%	2389
2018 Q1	$104K	Buy	566 +81	+17%	+$18.2K	﹤0.01%	2273
2017 Q4	$103K	Sell	485 -625	-56%	-$134K	﹤0.01%	2293
2017 Q3	$238K	Sell	1,110 -6	-0.5%	-$1.17K	﹤0.01%	2180
2017 Q2	$211K	Buy	+1,116	New	+$219K	﹤0.01%	2305

Other funds holding CRBP

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s CRBP Position: Q3 2020 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Corbus Pharmaceuticals (CRBP) in Q3 2020, closing a stake of 718 shares — an estimated $181K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in CRBP in Q2 2017 and held it in 13 quarters. The position peaked at $238K in Q3 2017. 122 funds tracked by Wall St. Rank hold CRBP as of Q3 2020.

Metropolitan Life Insurance Company (MetLife) reported no remaining Corbus Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 718 Corbus Pharmaceuticals shares in Q3 2020, an estimated $181K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Corbus Pharmaceuticals in Q2 2017 and held it in 13 quarters.
Metropolitan Life Insurance Company (MetLife)'s Corbus Pharmaceuticals position peaked at $238K in Q3 2017.
122 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2020.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q3 2020, filed 13 Nov 2020.